MARKET

ADMA

ADMA

Adma Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.275
+0.095
+4.36%
Opening 12:29 07/07 EDT
OPEN
2.150
PREV CLOSE
2.180
HIGH
2.306
LOW
2.100
VOLUME
1.86M
TURNOVER
2.41M
52 WEEK HIGH
2.315
52 WEEK LOW
1.010
MARKET CAP
446.70M
P/E (TTM)
-4.5473
1D
5D
1M
3M
1Y
5Y
ADMA's 6th plasma collection facility gets FDA approval
ADMA Biologics (NASDAQ:ADMA) said it received U.S. Food and Drug Administration (FDA) approval for its sixth ADMA BioCenters plasma collection facility, in Myrtle Beach, South Carolina. The company said on
Seekingalpha · 06/27 12:21
ADMA BioCenters Received FDA Approval for Sixth Plasma Collection Center, Located in Myrtle Beach, SC
ADMA Biologics, Inc. (NASDAQ: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it has received U.S.
Benzinga · 06/27 11:07
BRIEF-Adma Biologics Inc - Company Is On-Track To Have All 10 Plasma Collection Centers FDA-Approved By Year-End 2023
BRIEF-Adma Biologics Inc - Company Is On-Track To Have All 10 Plasma Collection Centers FDA-Approved By Year-End 2023
Reuters · 06/27 11:02
Shareholders in ADMA Biologics (NASDAQ:ADMA) have lost 50%, as stock drops 12% this past week
While not a mind-blowing move, it is good to see that the ADMA Biologics, Inc. ( NASDAQ:ADMA ) share price has gained...
Simply Wall St. · 06/26 13:11
BRIEF-Adma Biologics Announces Addition To The Russell 2000 Index
BRIEF-Adma Biologics Announces Addition To The Russell 2000 Index
Reuters · 06/21 13:44
ADMA biologics to enter Russell 2000 index
ADMA Biologics (NASDAQ:ADMA) will be added to the Russell 2000 Index, , according to a preliminary list of additions posted by FTSE Russell on June 17, 2022. The addition will
Seekingalpha · 06/21 11:20
ADMA Biologics Announces Addition to the Russell 2000® Index
Ramsey, N.J. and Boca Raton, Fla., June 21, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-der...
GlobeNewswire · 06/21 11:00
ADMA Biologics Set for Inclusion in Russell 2000 Index
MT Newswires · 06/21 09:37
More
No Data
Learn about the latest financial forecast of ADMA. Analyze the recent business situations of Adma Biologics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ADMA stock price target is 5.13 with a high estimate of 6.00 and a low estimate of 4.500.
High6.00
Average5.13
Low4.500
Current 2.275
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 147
Institutional Holdings: 112.92M
% Owned: 57.51%
Shares Outstanding: 196.35M
TypeInstitutionsShares
Increased
33
13.18M
New
24
4.58M
Decreased
23
9.35M
Sold Out
9
730.89K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.11%
Pharmaceuticals & Medical Research
+0.59%
Key Executives
Non-Executive Chairman/Independent Director
Steven Elms
President/Chief Executive Officer/Co-Founder/Director
Adam Grossman
Vice Chairman/Co-Founder/Director
Jerrold Grossman
Chief Financial Officer/Executive Vice President
Brian Lenz
Independent Director
Martha Demski
Independent Director
Bryant Fong
Independent Director
Lawrence Guiheen
Independent Director
Young Kwon
No Data
No Data
About ADMA
ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and markets specialty plasma-based biologics for the treatment and prevention of infectious diseases. It is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its patients include immune-compromised individuals who suffer from an underlying immune deficiency disorder and immune-suppressed for medical reasons. Its product candidates include BIVIGAM, an Intravenous Immune Globulin (IVIG) product indicated for the treatment of Primary Humoral Immunodeficiency (PI); ASCENIV an IVIG product indicated for the treatment of PI, and Nabi-HB which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (HBsAg). Its ADMA BioCenters subsidiary operates source plasma collection facilities in the United States. Its Plasma Collection Centers segment, provides a portion of its blood plasma for the manufacture of its products candidates.

Webull offers kinds of ADMA Biologics Inc stock information, including NASDAQ:ADMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADMA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADMA stock methods without spending real money on the virtual paper trading platform.